| Mar 9 2023 |
Real or Not Real? The Difference Between Legal Delta-8/Delta-10 THC and Illegal Delta-8/Delta-10 THCO |
Bradley Arant Boult Cummings LLP |
| Mar 9 2023 |
Patent Law Principles Apply to Claim Scope: Orange Book Delisting and Listing and Regulations |
McDermott Will & Schulte LLP |
| Mar 8 2023 |
This Week in 340B: February 28 – March 6, 2023 |
McDermott Will & Schulte LLP |
| Mar 8 2023 |
The FDA’s Proposed Rule on Food Labeling: Nutrient Content Claims and Definition of ‘‘Healthy’’ |
Stubbs Alderton & Markiles, LLP |
| Mar 8 2023 |
The Cannabis Paradox: Clarifying the Confusing Legality of Delta-8, THC-O, THCV, and Synthetically Derived THC |
Stark & Stark |
| Mar 7 2023 |
HHS-OIG Foregoes Sanctions On Drug Manufacturer For Providing Free Drugs To Patients Waiting For Insurance Authorization |
Barnes & Thornburg LLP |
| Mar 7 2023 |
DEA Proposes Rule for Post-PHE Telemedicine |
Sheppard, Mullin, Richter & Hampton LLP |
| Mar 7 2023 |
FDA Launches Dietary Supplement Ingredient Directory |
Keller and Heckman LLP |
| Mar 7 2023 |
Comments to CMS Guidance on the Medicare Prescription Drug Inflation Rebate Program Due March 11, 2023 |
Epstein Becker & Green, P.C. |
| Mar 7 2023 |
The Wait is Over . . . Or Is It? DEA’s Proposed Rules Around Telemedicine Prescribing: Initial Impressions and Key Takeaways |
Epstein Becker & Green, P.C. |
| Mar 7 2023 |
EPA Announces Both EPA and FDA to Conduct Virtual Public Meeting and Request Comments on Modernizing Their Approach to Oversight of Certain Products |
Bergeson & Campbell, P.C. |
| Mar 6 2023 |
Old North State Report – March 6, 2023 |
Nelson Mullins |
| Mar 6 2023 |
Federal Circuit Affirms Delisting of REMS System Patent from FDA Orange Book |
Mintz |
| Mar 6 2023 |
Update on FDA’s Prevention Strategies to Enhance Food Safety |
Keller and Heckman LLP |
| Mar 4 2023 |
NIOSH Announces Publication of Article on the Results of 2019 Survey of Engineered Nanomaterial Occupational Health and Safety Practices |
Bergeson & Campbell, P.C. |
| Mar 3 2023 |
Justice Department Announces Application Form for Marijuana Pardon Certificates |
The U.S. Department of Justice |
| Mar 3 2023 |
FDA Issues Draft Guidance on Labeling of Plant-Based Milk Alternatives |
Epstein Becker & Green, P.C. |
| Mar 3 2023 |
DEA Proposes Limited Post-PHE Telemedicine Prescription of Controlled Substances |
McDermott Will & Schulte LLP |
| Mar 2 2023 |
The Health AI Frontier: New Opportunities for Innovation Across the Health Care Sector |
Foley & Lardner LLP |
| Mar 2 2023 |
FDA Withdraws Proposed Rule on General Principles for Food Standards Modernization |
Keller and Heckman LLP |
| Mar 2 2023 |
Consumer Fraud PFAS Cases Continue To Rise |
CMBG3 Law |
| Mar 1 2023 |
North Carolina Senate Passes Compassionate Care Act – at Exactly 4:20 p.m. |
Bradley Arant Boult Cummings LLP |
| Mar 1 2023 |
Desperate Times, Desperate Measuring Cups – FTC Brings Enforcement Action for False “Made in USA” Advertising |
ArentFox Schiff LLP |
| Mar 1 2023 |
Unpacking Averages: Exploring New Data on FDA Responses to FOIA Requests |
Epstein Becker & Green, P.C. |
| Feb 28 2023 |
FDA Asked to Allow “Healthy” Claims on Coffee |
Keller and Heckman LLP |
| Feb 28 2023 |
China Announces Draft Standard on Nutritional Fortification Substances: What Will its Impact Be on Alternative Protein Foods? |
Keller and Heckman LLP |
| Feb 28 2023 |
Will the U.S. Supreme Court Make Marijuana Legal? |
Bradley Arant Boult Cummings LLP |
| Feb 28 2023 |
This Week in 340B: February 21 – 27, 2023 |
McDermott Will & Schulte LLP |
| Feb 27 2023 |
Old North State Report – Feb. 27, 2023 |
Nelson Mullins |
| Feb 27 2023 |
FDA Publishes List of 2023 Priority Guidance Topics |
Keller and Heckman LLP |
| Feb 27 2023 |
DEA Announces Permanent Flexibilities for the Prescribing of Controlled Substances via Telemedicine |
Polsinelli PC |
| Feb 27 2023 |
DEA’s Proposed Rules on Telemedicine Controlled Substances Prescribing after the PHE Ends |
Foley & Lardner LLP |
| Feb 25 2023 |
No Surprises Act Update: Certified IDR Entities to Resume Payment Determinations for Services Furnished Before October 25, 2022 |
Sheppard, Mullin, Richter & Hampton LLP |
| Feb 25 2023 |
HHS-OIG Declines to Impose Sanctions on Drug Manufacturer for Financial Assistance to Pediatric Patients with Rare Disease |
Barnes & Thornburg LLP |
| Feb 24 2023 |
Cosmetics – Moving From Voluntary Compliance to Mandatory Regulation |
Beveridge & Diamond PC |
